After Axsome Therapeutics (AXSM) reported topline data from the studies of AXS-05 in Alzheimer’s disease agitation, Truist analyst Joon Lee noted that while the ADVANCE-2 study missed statistical ...
On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) reported fourth-quarter 2024 revenues of $118.77 million, up from $71.53 million a year ago, beating the consensus of $117.64 million. Auvelity (oral ...
FDA grants Priority Review to AXS-05 (dextromethorphan/bupropion) for the treatment of agitation associated with Alzheimer disease.
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Shares of Axsome Therapeutics AXSM were up 22.8% on Dec. 31, after it announced that the FDA had accepted the supplemental new drug application (“sNDA”) seeking approval for AXS-05 (dextromethorphan ...
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a ...
AXS-05 met the primary endpoint by substantially and statistically significantly delaying the time to relapse of Alzheimer’s disease agitation as compared to placebo (hazard ratio for time to relapse ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, George T. Grossberg, MD, discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results